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Microglia are intrinsic components of the brain immune system and are activated in many central nervous system disorders. ,e
ability to noninvasively image these cells would provide valuable information for both research and clinical applications. Today,
most imaging probes for activated microglia are mainly designed for positron emission tomography (PET) and target translocator
proteins that also reside on other cerebral cells.,e PET images obtained are not specific for microglia-driven inflammation. Here,
we describe a potential PET/MRI multimodal imaging probe that selectively targets the scavenger receptor class A (SR-A)
expressed on activated microglia. ,ese sulfated dextran-coated iron oxide (SDIO) nanoparticles are avidly taken up by microglia
and appear to be nontoxic when administered intravenously in a mouse model. Intravenous administration of this SDIO
demonstrated visualization by T∗2 -weighted MRI of microglia activated by intracerebral administration of tumor necrosis factor
alpha (TNF-α).,e contrast was significantly enhanced by SDIO, whereas there was little to no contrast change in animals treated
with nontargeted nanoparticles or untreated controls. ,us, SR-A targeting represents a promising strategy to image activated
microglia in the brain.
1. Introduction
Inflammation occurs in various central nervous system dis-
eases, such as neurodegenerative diseases, epileptic disorders,
as well as autoimmune diseases. Microglia, the resident
macrophages in the brain, are recognized as the prime com-
ponents of an intrinsic brain immune system and are the key
cellular mediators of neuroinflammatory processes [1]. ,e
activation of microglia can be triggered by an assortment of
inflammatory stimuli to the central nervous system (CNS) that
includes stroke, seizures, Alzheimer’s disease (AD), traumatic
brain injury, and CNS storage diseases [2–6]. Activated
microglia are capable of synthesizing a broad range of
proinflammatory and anti-inflammatory cytokines and other
molecular mediators [7] that can lead to changes in the
permeability of the blood-brain barrier followed by infiltration
of peripheral immune cells into the CNS, increased secretion
of inflammatory cytokines, exacerbated tissue damage, and
neuron loss [8]. ,us, noninvasive methods for identifying
activated microglia in vivo could lead to earlier detection of
neuroinflammation and provide a means for monitoring
disease progression and therapeutic intervention.
Earlier efforts have reported the development of in vivo,
neuroinflammatory PETdiagnostic agents targeting activated
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microglia through the peripheral benzodiazepine receptor
(PBR), now known as the 18 kDa translocator protein
(TSPO). 11C-PK11195 is one of the most widely used ligands
for PET imaging of microglia in patients with neurological
disorders, but this first-generation TSPO radiotracer dem-
onstrates poor signal-to-noise ratio and poor selectivity
[9, 10]. Newer tracers, such as 11C-PBR28, with improved
TSPO binding or selectivity have been introduced and ini-
tiated in clinical studies [11–13]. Unfortunately, TSPO genetic
polymorphism can adversely affect the binding of 11C-PBR28
leading to signal variability [14, 15]. ,e density of TSPO in
the brain is very low, even in a neurodegenerative setting [16],
and the presence of TSPO on other brain cell types reduces
the specificity of TSPO [17] and its PET signal coregistered
with both activated microglial cells and reactive astrocytes
following LPS induced inflammation [10]. A more selective
biomarker for activated microglia that could be visualized by
PET or high-resolution MRI would be of therapeutic value.
Instead of using TSPO as a target, we labeled activated
microglia through the scavenger receptors class A (SR-A). SR-
A type scavenger receptors have been shown to be upregulated
on activated microglia in pathological states and not present
on quiescent adult microglia [18]. SR-A initiates inflammatory
responses by recognizing pathogen- or damage-associated
molecular patterns (DAMPs) [19]. SR-A expression is asso-
ciated with the activation/polarization of the microglia. Be-
cause of their role in inflammation, SR-A receptors are not
downregulated with ligand concentration. ,ey also mediate
very efficient and rapid internalization of bound ligand [20]
and repeatedly recycle through the endosomal compartment,
illustrating desirable traits as targets for labeling [21–24].
Previously, our group has developed iron oxide-based
PET/MRI probes that are targeted to activated macrophages
through the SR-A type scavenger receptors to image vul-
nerable atherosclerotic plaques [25–27]. Given the presence
of this same receptor on activated microglia, in this work we
investigate an improved imaging probe and demonstrate the
ability to specifically label and image activated microglia in
a mouse model of brain inflammation [28]. ,e probe is
sulfated dextran-coated iron oxide (SDIO) nanoparticles
conjugated with the macrocyclic chelator 1,4,7,10-
tetraazacyclododecane-1,4,7-triacetic acid (DO3A); the
surface sulfation allows for specific targeting to SR-A. Sul-
fated dextran (a.k.a. dextran sulfate) is widely known as one
of the ligands for SR-A with a Kd of 3 nM [29]. In our
previous study, we have confirmed that the sulfation of
dextran coating significantly improved the cellular binding
and uptake of these nanoparticles by macrophages and the
uptake efficiency enhances with higher level of surface
sulfation [30]. ,e sulfated dextran-coated iron oxide
nanoparticles have a similar binding affinity to the SR-A,
compared with dextran sulfate itself. ,us, we hypothesize
that these particles will also serve as promising imaging
probes to visualize activated microglia in vivo. From the
series of nanoparticles that we reported in previous work,
SDIO-DO3A-10 had the highest surface sulfation level and
best uptake efficiency [30]. SDIO-DO3A-10 and the non-
sulfated analog DIO-DO3A are used in this study and re-
ferred to as SDIO and DIO, respectively. Here, we
demonstrate the specific targeting of SDIO to activated
microglia in vitro and their efficient MRI contrast en-
hancement ability in a mouse model of brain inflammation
as a first step in validation for microglia imaging.
2. Materials and Methods
2.1. General Materials. Materials were purchased from
commercial suppliers and used directly, unless specifically
noted. Human TNF-α was purchased from PeproTech Inc.
(Rocky Hill, NJ). Sulfated dextran-coated iron oxide was
synthesized as described in our previous paper [30]. Lipo-
polysaccharides were purchased from Sigma-Aldrich (St.
Louis, MO). Fetal bovine serum (FBS), L-glutamine, and
Dulbecco’s phosphate-buffered saline (DPBS) (1x) were
from GIBCO. Lipoprotein-deficient bovine serum (LPDS)
was obtained from Biomedical Technologies, Inc. (Stoughton,
MA). Murine BV2 microglia were obtained from American
Type Culture Collection (ATCC). Saline and isoflurane were
acquired from APP Pharmaceuticals, LLC (Schaumburg, IL),
and Piramal Healthcare Limited, respectively. Buprenex In-
jectable was received from Reckitt Benckiser Healthcare Ltd.
Beuthanasia-D Special was purchased from Schering-Plough
Animal Health Corp.
2.2. Syntheses of DIO and SDIO. Nanoparticles were syn-
thesized and characterized as previously described in detail
[30]. Briefly, dextran-coated iron oxide (DIO) nanoparticles
were synthesized by coprecipitation of iron salts and reduced
dextran with the addition of ammonium hydroxide. Purified
DIO was conjugated with the DO3A chelator, which has
high stability for copper-64 ions. ,is generated multimodal
function for either PETor MRI applications. Conjugation of
the chelator is a two-step reaction directly coupling to the
hydroxyl groups in the dextran coating, and we sulfated the
dextran coating after conjugation of the chelator to maxi-
mize the sulfate level on the surface. ,e highest sulfation
level was used to synthesize SDIO nanoparticles. Extensive
physical characterizations such as dynamic light scattering
for hydrodynamic size distribution, transmission electron
microscopy (TEM) for iron oxide core size, atomic ab-
sorption spectroscopy (AAS) for iron content percentage,
combustion infrared for sulfur content percentage, and
relaxivity measurements were performed on both non-
sulfated precursor DIO and SDIO nanoparticles.
2.3. Biocompatibility. Biocompatibility of SDIO on murine
BV2 microglia was evaluated using C12-resazurin viability
assays. BV2 cells were maintained in Dulbecco’s Modified
Eagle Medium (DMEM) containing 10% fetal bovine serum
(FBS) and penicillin-streptomycin (100U/mL) at 37°C in
a humidified 5% CO2 atmosphere. To perform the viability
experiments, BV2 cells were plated in 96-well plates at
a concentration of 104 cells per well and incubated in a 5%
CO2 atmosphere at 37°C overnight. ,e medium was then
replaced with fresh media containing varying concentrations
of SDIO (at 0.04, 0.2, 1, 4, 10mM [Fe]) and incubated for 4
or 24 h. ,e medium was then removed, and the cells were
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washed with Dulbecco’s phosphate-buffered saline solution
(DPBS) three times. Media containing C12-resazurin (5 μM)
was then added to the wells, and after a 15min incubation,
fluorescence was measured on a Safire2 monochromator
microplate reader (Tecan Austria, Groedig, Austria) with
excitation at 563 nm and emission at 587 nm.
2.4. Cellular Uptake Studies. To study the specific cellular
uptake of SDIO nanoparticles by microglia, BV2 cells (be-
tween passages 20 and 40) were grown/maintained in
Dulbecco’s Eagle’s minimum essential medium (DMEM)
containing 10% fetal bovine serum (FBS) and penicillin-
streptomycin (100U/mL) in 5% CO2 and then plated in
6-well plates at a concentration of 1× 106 cell/well (2mL).
After reaching ∼80% confluency, plated cells were rinsed
twice with Dulbecco’s phosphate-buffered saline solution
(DPBS) and activated through exposure to lipopolysac-
charide (LPS) in serum-free media at a final concentration of
200 ng/well for 6 h. Activated BV2 cells were incubated with
DIO or SDIO solutions at different concentrations (25, 50,
and 100 μM iron) for 1 h. Plated cells were then rinsed three
times with DPBS. Deionized water (1mL) was then added,
and the freeze/thaw (30min/20min) method was repeated
twice to lyse cells. Cell lysates were lyophilized, and DI water
(0.3mL) was added to the residue to prepare the solution for
T2 measurement by the Bruker Minispec mq60. T2 values
were measured using a Carr–Purcell–Meiboom–Gill se-
quence, with τ � 1ms and 200 data points.
2.5. In Vivo Study. All animal experiments were performed
under a protocol approved by the UC Davis Institu-
tional Animal Care and Use Committee (UCD Institutional
# 18025). BALB/c mice (18–22 g, 9 weeks old) were obtained
from Charles River Laboratories, Wilmington, MA. SDIO
and DIO were evaluated after intravenous (IV) adminis-
tration in mouse models of cerebral inflammation and in
control animals. Brain inflammation was induced by uni-
lateral intracerebral injection of human TNF-α according to
a protocol previously reported in the literature [28]. Four
experimental groups were evaluated: (1) TNF-α only (n � 4),
(2) TNF-α+ IV-SDIO (n � 4), (3) TNF-α+ IV-DIO (n � 4),
and (4) IV-SDIO only (n � 4). Mice in group 1 received
intracerebral inoculation of TNF-α to assess whether the
chemically induced inflammation in the brain produced
endogenous contrast changes. ,e ability of intravenous
SDIO or DIO to enhance contrast onMR images of inflamed
brains was tested in the groups 2 and 3. Group 4 was
designed to evaluate the impact of SDIO on the normal
brain. ,e timeline of this study is shown in Figure 1.
,e unilateral intracerebral injection protocol consisted
of isoflurane anesthesia (1–5% inhalation route, typically at
3% induction, 1.5–2% maintenance) of animals and place-
ment into a stereotactic device maintained at 37± 0.2°C on
a feedback-controlled heating pad.,e scalp was shaved and
prepared using 3 cycles of betadine and isopropyl alcohol
prior to any incisions. A small burr hole was drilled on the
left side into the skull of the mice, and TNF-α (1 μg in 1 μL)
was injected (at coordinate 0.5mm anterior, 2.0mm lateral,
and −3mm ventral to the bregma) through a 26-gauge
needle within a period of 3 minutes [28]. ,e opening was
sutured using an Ethilon nylon suture with 18″ and P-3
reverse cutting. Buprenex (0.1mg/kg) was administered
subcutaneously at the end of the procedure and then 2 times
daily for 48 h.,e animals were monitored regularly for pain
or discomfort.
Four milligrams of SDIO was dissolved in 150 µL of
injectable saline in a 1.5mL Eppendorf vial and vortexed for
5 seconds to obtain a uniform solution. ,e solution was
then passed through a 0.2-micron filter for sterilization and
ready for injection. Animals were anesthetized under iso-
flurane, and SDIO was administered intravenously via tail
vein with up to 150 μL, 20mg/kg of Fe, 24 h after in-
tracerebral injection of TNF-α. Control animals were in-
jected with the untargeted probe, DIO, of comparable
composition to the experimental probe being tested. ,e
injected dose was adjusted to match the same iron content as
20mg/kg of animal.
2.6. MRI and Signal Processing. All images were acquired
from a 7-Tesla (300MHz) Bruker Avance Biospec system
(Billerica, MA) equipped with a 95mT/m max gradient set
and 35mm ID Doty coil, at ambient temperature (25°C).
Anesthesia (isoflurane, inhalation, 1–3%) was administered
during imaging acquisition. ,e animals were imaged 22 h
after intracerebral injection of TNF-α and imaged again 4,
24, and 48 h after imaging probe injection (illustrated in
Figure 1). A water heating pad was used on the animal
holder and maintained at 37°C to prevent hypothermia.
Each animal was imaged by T∗2 -weighted sequences
(FLASH 2D) with TR � 500ms, TE � 5ms, angle� 24°,
NA � 8, FOV� 20 × 20mm2, matrix � 128×128, slice
thickness � 0.67mm, and 12 slices.
Signal intensity and background noise for each 0.67mm
T∗2 -weighted image slice was determined using Image J/Fiji
software [31]. To compare particle uptake between time
points and subjects, we calculated the contrast-to-noise ratio
(CNR) generated by the probes on T∗2 -weighted images.
CNR was calculated as the difference in signal intensity
between the injured site and the control region in the
contralateral side of the brain scaled to image background
noise. ROIs were drawn manually at the level of the injured
site and were similar between all imaging time points.
Day 1
TNF-α injection 
on adult mice 
(9 weeks old)
MRI scans 22 h 
post-TNF-α
injection (pre-IV)
IV injection of SDIO 
particles, 24 h after 
TNF-α injection 
MRI scans 
48 h after IV 
injection
MRI scans 
4 h after IV 
injection
Transcardial 
perfusion and 
fixation
MRI scans 
24 h after IV 
injection
Day 2 Day 3 Day 4
Figure 1: Overview of the in vivo study timeline.
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2.7. Histology Analysis. Immediately following the final
imaging time point at 48 h, the animals were anesthetized by
high dose of anesthesia solution (Euthasol, 100mg/kg, i.p.)
followed by transcardial perfusion with phosphate-buffered
saline (0.9%) and 10% buffered formalin phosphate solution.
Brain tissue was dissected and postfixed in 10% buffered
formalin phosphate solution at 4°C. ,en, they were cry-
oprotected by incubation overnight in sucrose 30% solution.
Forty-micrometer-thick coronal brain sections were cut on
a freezing microtome (SM2400; Leica Microsystem,Wetzlar,
Germany), and free-floating serial sections were preserved in
a storing solution (glycerol 30%, ethylene glycol 30%, dis-
tilled water 30%, and PBS 10%) at −20°C until use.
Each brain was then processed for a double staining for
microglia (anti-Iba-1 antibody) and iron (Perls’ Prussian
blue staining). Free-floating sections were rinsed in PBS
0.1M and incubated with hydrogen peroxide 0.3% for
20 minutes. Pretreatment in a blocking solution for 30
minutes (PBS-Triton X-100, 0.2% (Sigma-Aldrich, MO,
USA) and 4.5% normal goat serum) was performed before
a 48-hour incubation, at +4°C, with the anti-Iba-1 antibody
(Wako-019-19741, 1/1000 (Neuss, Germany)). ,en, sec-
tions were incubated for 1 hour in secondary biotinylated
anti-rabbit antibody (Vector Laboratories, 1/1000, Burlin-
game, CA, USA) before revelation. ABC Vectastain kit
(Vector Laboratories, 1/250, Burlingame, CA, USA) was
used for DAB revelation (DAB SK4100 kit, Vector Labo-
ratories, Burlingame, CA, USA). ,e floating sections were
then mounted on slides before Perls’ staining, performed the
next day. For Perls’ staining, the slides were incubated in
a methanol 20% and hydrogen peroxide 3% solution for 10
minutes.,ey were rinsed with distilled water and PBS 0.1M
before to be incubated with 2% potassium ferrocyanide
(P9387, Sigma-Aldrich) and 2% hydrogen chloride solution
for 20 minutes. ,e sections were finally dehydrated, cov-
ered by a cover slip, and digitized with a Zeiss AxioScan.Z1
(Oberkochen, Germany) whole-slide imaging microscope at
a lateral resolution of 0.5 μm.
2.8. Statistical Analysis. Unpaired two-tailed t-test was used
to compare the means between different groups. A t statistic is
calculated with t� difference in sample means/SE of differ-
ence in sample means. A P value is obtained by comparison
with the t distribution on degrees of freedom. P< 0.05 was
then considered significant. Nonparametric Mann–Whitney
U test was also performed for the in vivo study (N � 4) to
compare with the parametric t-test.
3. Results
3.1. Syntheses and Characterization of DIO and SDIO.
,e synthesis and physical characterization of both DIO and
SDIO were reported in a previous article [30].,e properties
of the materials synthesized for the current studies were
confirmed to match to our published results. A schematic
representation of SDIO is shown in Figure 2; DIO is the
nonsulfated analog. Both types of nanoparticles had an iron
oxide core size of 6 nm.,e average hydrodynamic diameter
of DIO and SDIO was around 20 and 60 nm, respectively.
,e increased size of SDIO was likely due to the repulsion
between the negatively charged sulfate groups on the
surface, which made the dextran coat expand. ,e iron
content by total mass was 20% in DIO and 10% in SDIO.
,e zeta potential of the sulfated nanoparticles was −45mV,
while DIO had a positive charge of +11.7 mV in
deionized water. Both nanoprobes had high relaxivities
(DIO: r1 � 17.9 mM−1·s−1, r2 �103.3 mM−1·s−1; SDIO:
r1 � 14.2 mM−1·s−1, r2 � 72.8 mM−1·s−1), and the high
r2/r1 ratios are indicative of good negative contrast
agents. ,e decrease in relaxivity after sulfation could be
due to the thicker coating of SDIO nanoparticles, which
increases distance of the core from surrounding water,
could reduce water exchange through the polysaccharide
layer, and modulate relaxivity.
3.2. SDIO Is Biocompatible to Microglia. In our previous
work, SDIO nanoparticles were evaluated on cultured liver
cells (HepG2) and macrophages (J774 and P388D1) without
observable toxicity. C12-resazurin viability assays were also
used here to quantify cell viability on microglia. Cellular
survival following incubation with increasing concentra-
tions of SDIO is shown in Figure 3. Untreated cells (blank)
served as the control. Fluorescent intensities, which reflected
fractional survival of treated cells, were normalized against
the signal intensities from the untreated cells. ,e average
viability exceeds 95% after 4 or 24 h incubation with
nanoparticles. An unpaired, two-tailed t-test was performed
to compare treated cells against the control within each time
point. ,ere was no significant difference (P> 0.5) between
the untreated cells and those incubated with SDIO at
concentrations up to 5mM, a concentration range relevant
for in vivo MRI imaging.
3.3. High Cellular Uptake of SDIO by Microglia. In our
previous study with murine macrophages, sulfation of DIO
facilitated SR-A targeting and enhanced microglial uptake.
,ere was also a trend that uptake efficiency increased with
higher sulfation levels on the nanoparticles. In this work, we
identified the same trends when assessing the uptake of
SDIO and DIO by microglia (BV2 cells) at 37°C. ,e T2
values of the cell lysates of microglia incubated with SDIO or
DIO for 2 h are shown in Figure 4. ,ere was significantly
O
O
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N
H
Dextran coating
Iron oxide core
OSO3–
OSO3–
OSO3–
OSO3–OSO3–
OSO3–
Figure 2: Schematic representation of SDIO.
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less uptake of the untargeted DIO (black bar) at 25, 50, and
100 µM. With sulfation on the nanoparticles, the T2 de-
creased greatly for cells incubated with SDIO. T-test sta-
tistical calculations confirmed significant differences
between the untreated cells and those incubated with SDIO
(P< 0.001), while the difference between untreated cells and
cells treated with DIO was not significant (P> 0.3), in-
dicating that there was very little nonspecific uptake of
nanoparticles by microglia. As the transverse relaxivity of
SDIO (72.8mM−1·s−1) was smaller than that of DIO
(103.3mM−1·s−1) due to the surface modification, there is
actually an additional 1.4-fold increase in particle uptake
efficiency for SDIO compared to that of DIO. ,is indicates
that the surface sulfation significantly improved targeting to
microglia and far exceeded the compensation for the de-
crease in relaxivities. ,is expected result suggested that
more SDIO nanoparticles could accumulate in activated
microglia when intravenously injected compared to in-
jection of the same amount of the untargeted DIO.
3.4. In Vivo Visualization of Inflammation and Histological
Confirmation. A mouse model of brain inflammation gen-
erated by unilateral intracerebral injection of TNF-α was
previously reported in the literature [28]. TNF-α is a key
regulator of the inflammatory response with its strong effect
on vascular endothelium and endothelial leukocyte in-
teractions [32]. In response to TNF-α, endothelial cells
promote inflammation by displaying adhesion molecules for
leukocyte recruitment. Here, to verify that intravenous ad-
ministration of SDIO specifically detects neuroinflammation,
we imaged the following groups: (1) TNF-α-only group
(n � 4), (2) IV-SDIO-only group (n � 4), (3) TNF-α+ IV-
SDIO group (n � 4), and (4) TNF-α+ IV-DIO group (n � 4).
As shown in Figure 5(a) (row 1), MR images of animals
from the TNF-α-only group did not show much signal
change 22 hours after TNF-α inoculation (before IV). ,e
needle track at this time point was barely observable. MRI
recorded 28 hours after surgery (4 h after IV) revealed only
slightly enhanced negative contrast along the needle track
(red arrows in Figure 5(a), row 1). ,ese changes became
more visible 24 and 48 hours after IV.,is is probably due to
increased inflammation and microhemorrhages with time.
On the histological image, a small cavitation representing
tissue loss was also detected. Anti-Iba-1 antibody staining
confirmed the presence of activated microglia along the site
of TNF-α inoculation (Figures 5(b) and 5(c)). A slight Perls’
positive staining was also detected in the vicinity of the
lesion, likely due to microhemorrhages along the needle
track (Figures 5(b) and 5(c)).
MR images of the IV-SDIO-only control group (Figure
5(a), row 2) exhibited no accumulation of contrast in the
intact brain as expected, suggesting that in the absence of
cerebral inflammation and blood-brain barrier (BBB) dis-
ruption, the nanoparticles do not cross the BBB to accu-
mulate in the brain. ,e histological staining (Figures 5(d)
and 5(e)) did not demonstrate notable iron staining.
We compared T∗2 -weighted contrast of the glial scar
produced by intracerebral TNF-α treatment groups and in
groups that then received intravenous administration of
either SDIO or DIO (Figure 5(a), rows 3 and 4, resp.).
Twenty-two hours after unilateral (left) TNF-α inoculation,
prior to contrast injection, no obvious signal changes could
be detected at the site of the inoculation in any group
(Figure 5(a), before IV). Four hours after IV injection of
SDIO, the MR images displayed an area with strong negative
contrast in the left side of the brain where TNF-α was in-
jected (Figure 5(a), row 3). ,e region of T∗2 signal hypo-
intensity was larger and through a greater brain depth in the
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Figure 4: Specific uptake of SDIO nanoparticles by BV2 cells
compared to nonsulfated analog DIO. Accumulation of iron oxide
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Figure 5: Continued.
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SDIO group (row 3) than the TNF-α group that received
DIO (row 4). ,ere was no signal alteration in the control
contralateral cortical hemisphere consistent with prefer-
ential uptake of the SDIO particles at the sites of focal
inflammation. Quantitative analysis showed that CNR
(calculated as the difference in signal intensity between the
injured site and the control region in the contralateral side
of the brain scaled to image background noise) reached 17
at 4 h post-IV injection scan (Figure 6). ,e absence of
detectable signal changes in the MRI scan immediately
after surgery and before SDIO injection (Figure 5(a))
indicates that the subsequent hypointensities following
SDIO in the treated left hemisphere were a consequence of
uptake of the iron oxide nanoparticles. Pathology did not
demonstrate evidence of acute hemorrhage. ,e negative
contrast was strongest at 24 h post-IV injection (Figure
5(a), row 3) and the CNR reached 49 (14-fold increase
from the pre-IV scan) at this time point (Figure 6), which
suggests higher accumulation of SDIO at the inflammatory
site. ,e negative contrast then weakened slightly by 48 h
post-IV injection and the CNR decreased to 26 (Figures
5(a) and 6).
For the TNF-α+ IV-SDIO group, histological evalua-
tions (Figures 5(f) and 5(g)) showed a small cavitation (blue
arrow), a consequence of local cellular death following direct
TNF-α instillation, representing a loss of dead or dying brain
tissue during histological processing. TNF-α induced cavi-
ties were nonhemorrhagic and narrower in caliber than the
corresponding broad T∗2 hypodensities visualized 24 and
48 h. Anti-Iba-1 antibody staining confirmed the presence of
activated microglia at the site of TNF-α inoculation. We also
found blue staining throughout the inflammatory lesion,
indicating iron oxide nanoparticles accumulated in the in-
jured hemisphere.,e colocalization of the immunostaining
and iron staining showed that iron oxide accumulated in
microglia at the inflammatory sites and there was a strong
correlation with the extent of iron staining to the contrast
enhancement on the T∗2 -weighted images.
Unlike the TNF-α+ IV-SDIO group, the TNF-α+ IV-
DIO group did not present pronounced signal change after
TNF-α inoculation (Figure 5(a) row 4 and Figure 6). Similar
to the TNF-α-only group, the TNF-α+ IV-DIO group dis-
played slightly enhanced negative contrast along the needle
track but with very weak contrast compared to the TNF-
α+ IV-SDIO group, and the CNR in the TNF-α+ IV-DIO
group was under 10 for all time points. A significant dif-
ference between the TNF-α+ IV-SDIO and TNF-α+ IV-
DIO conditions was reached 24 and 48 hours after the IV
injection of the contrast agents (Figure 6, unpaired t-test
P< 0.05). As the group size was small (N � 4), we also
(h) (i)
Figure 5: Representative T∗2 -weighted MRI and histological staining of mouse brains from different imaging groups. (a) T∗2 -weighted MR
images in each row represent MRI scans at different time points from the same animal in that group. ,e second row is an animal that did
not receive intracerebral injection, only intravenous SDIO injection. ,e other three rows are animals that underwent TNF-α intracerebral
injections. From left to right, column 1 represents images after TNF-α injection, but before IV injection of contrast agent, the rest of the
columns of MRI represent time points after intravenous injection of stated contrast agent (except for row 1, these animals were not injected
with contrast agents). Red arrows denote the needle tracks and regions highlighted by contrast agents. (b–i) Histological evaluation of the
same animals as shown in (a): (b, c) TNF-α only; (d, e) IV-SDIO only; (f, g) TNF-α+ IV-SDIO; (h, i) TNF-α+ IV-DIO. Blue arrows in (b),
(f ), and (h) denote small cavities in the brain that were observed. Images (c), (e), (g), and (i) showmagnification of Iba-1 and iron staining of
selected areas (red square) from images (b), (d), (f ), and (h). Activated microglia at inflammation sites were stained brown by Iba-1 antibody,
while iron oxide nanoparticles accumulated in the vicinity region were stained blue by Perls’ Prussian blue. Scale bars represent 200 µm.
60
50
40
30
20
10
0
SDIO
DIO
CN
R
Before IV 4 h 24 h 48 h
∗
∗∗
Figure 6: Average CNR of SDIO and DIO from MR images at
different time points. All four animals from the experimental
groups were calculated. ∗P< 0.05, ∗∗P< 0.01. All error bars present
SEM (n � 4).
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performed Mann–Whitney U test to compare the CRN of
IV-SDIO and IV-DIO at different time points. Mann–
Whitney U is a nonparametric test that does not require the
assumption of normal distribution and suits better for small
sample size. U at 4 h, 24 h, and 48 h after IV was 4, 1, and 0,
respectively. Similar to the t-test, a significant difference
(P< 0.05) was also found between the TNF-α+ IV-SDIO
and the TNF-α+ IV-DIO groups at 48 h post-IV injection.
,ese results suggested inefficient uptake of DIO by
microglia in the inflamed region. Histological results from
the TNF-α+ IV-DIO group also showed a small cavitation
and activated microglia at the site of TNF-α inoculation
(Figures 5(f) and 5(g)).
,ese results indicate that, with the same injected iron
dose, SDIO accumulated preferentially compared to DIO
particles at the sites of TNF-α inoculation, that is, neuro-
inflammation. ,us, sulfated nanoparticles are excellent,
targeted contrast agents that enhance signal from microglia
in vivo compared to conventional dextran-coated iron oxide.
,e result parallels that from the in vitro uptake studies
(Section 3.3) where SDIO nanoparticles were more effi-
ciently and avidly taken up by BV2 cells. ,e marked
specificity of SDIO uptake by microglia is in contrast to
SDIO uptake by macrophages that we have previously re-
ported: microglia seem to show negligible uptake of the
nontargeted DIO particles while macrophages showed re-
duced but measurable in vivo uptake of DIO [27]. ,e la-
beling of activated microglia by SDIO, thus, is comparatively
much more selective than that of activated macrophages.
4. Discussion
MRI has shown great clinical utility for its high-resolution,
noninvasive imaging of the brain without using ionizing
radiation. Visualizing information about inflammatory
processes such as activation of microglia can contribute to
the understanding of the progression of neurotoxicity and
cognitive impairment, facilitating development of improved
treatments for neurodegenerative diseases. Previous studies
have attempted to use endogenous iron deposits in activated
microglia to generate contrast on MR images [33]. However,
the poor signal from endogenous iron-labeled microglia
limits the approach for a general assessment in the brain.
,us, various imaging agents have been under development
to detect focal accumulations of activated microglia by MRI.
Fleig and colleagues previously reported labeling activated
microglia with untargeted, ultrasmall superparamagnetic iron
oxide (USPIO) nanoparticles in culture and in a rat glioma
model [34]. Confocal microscopy of isolated brain sections
showed localization of USPIO in microglia and macrophages.
Although there is inflammatory activity that can sequester
nontargeted agents, microglial uptake of USPIO was not
efficient and transport was presumably through the enhanced
permeability and retention effect. Previous MRI studies in
animal models have used dextran-coated iron oxide doses up
to 30mg/kg body mass, 60 times the normal human dose
(0.56mg of iron/kg body weight [35]). ,is suggested that
improved targeting and sequestration by microglia could
reduce dose requirements.
,rough SR-A, microglia interact with many compo-
nents of cerebral inflammatory injury, such as oxidized low-
density lipoprotein, amyloid fibrils, and apoptotic neurons
[36, 37]. SR-A receptors have broad ligand specificity for
a diverse array of polyanionic macromolecules, such as
maleylated bovine serum albumin (mal-BSA), oxidized LDL,
malondialdehyde-modified LDL, and polyinosinic acid
[38–41]. ,e SR-A-targeted probes that we have developed
indicate a significant improvement in the targeting and
uptake of sulfated dextran-coated iron nanoparticles.
Here, we provide a first proof that SDIO labels in vivo
microglia activated by intracerebral administration of
TNF-α. In normal brain where the BBB is intact, entry of
nanomaterials is very restricted, as passive diffusion
of substances across the BBB endothelial cells is normally
limited to small, lipophilic molecules less than 500 Da
[42]. In this study, we wanted to focus on the targeting of
microglia by SDIO and designed a TNF-α-based protocol
inducing microglial activation associated with BBB dis-
ruption. SDIO but not the untargeted DIO particles
showed significant labeling ability. ,is supports that
labeling by SDIO is not simply due to microglial se-
questration of material that passively diffused across the
open BBB. First applications of SDIO without further
modification of the contrast agents could thus target
pathologies such as traumatic injuries, multiple sclerosis,
or brain tumors in which the BBB is temporarily opened
or chronically damaged [43].
Although it has long been known that BBB compromise
commonly occurs in inflammation, infection, and all neu-
rodegenerative disorders [44, 45], the damage to the BBB can
be much milder than the trauma generated by intracerebral
injections. ,us, SDIO may require modifications to pen-
etrate the brain in applications where the BBB is not, or only
slightly, opened. All nanoparticle-based agents face the
challenge of penetrating the blood-brain barrier, and
a number of methods described in the literature to overcome
the BBB, such as the opening of tight junctions using os-
motic pressure or ultrasound disruption, can effectively
generate pores in the BBB that enable the entry of imaging
agents or therapeutics to the brain [46, 47]. Future studies
will need to modify SDIO and evaluate the improved for-
mulation in models with milder BBB disruptions.
Transport of materials across the BBB is an active area of
study by others, and previous works have demonstrated that
coating nanoparticles with ligands (such as insulin or
transferrin) or surfactants (such as polysorbate 80) could
improve the passage through blood-brain barrier after
systemic administration [48–50]. Surfactants can either
directly disrupt the tight junctions or allow NPs absorbing to
plasma protein, such as apolipoprotein E, to cross the BBB
through endothelial cells by receptor-mediated transcytosis
or endocytosis [51]. It has also been shown that magnetic
heating (hyperthermia) of magnetic nanoparticles by a low
radiofrequency field can increase BBB permeability without
perturbing other brain cells [52].,is transient disruption of
BBB is local and entirely reversible and could be potentially
achieved by our SDIO nanoparticles. Methods that can keep
SDIO in circulation longer and mediate transport across the
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BBB will greatly increase efficiency for detection of microglia
in the brain and are topics for our future studies.
Future studies may also focus on the use of SDIO for
other imaging methods. It is interesting to note that SDIO is
conjugated with a macrocyclic chelator, which captures
radionuclides including 64Cu, so that it could potentially be
employed as a PETor PET/MRI multimodal agent [53]. PET
is a very sensitive method, and SDIO-based contrast agents
could be beneficial where low numbers of activated
microglia are to be visualized or in diseases in which the
crossing of BBB by SDIO is low.
5. Conclusions
We demonstrated the ability of SDIO targeting SR-A to
image microglia actively involved in brain inflammation.
,e functionalized iron oxide nanoparticles were proven to
be nontoxic and were efficiently internalized by activated
microglia in vitro and in vivo. In a mouse model of brain
inflammation, SDIO rendered much better in vivo contrast
enhancement compared to the nonspecific, nonsulfated
analog. ,ese results support that SDIO is a promising MRI
contrast agent, with potential multimodal function, to image
activated microglia in inflammation and assess disease
progression.
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